Safety and Efficacy of PDL-0101 in Patients With Hyperlipidemias: a Pilot Study.
Safety and Efficacy of PDL-0101 in Patients With Hyperlipidemias: a Pilot Study.
This will be an 8 week multicenter, randomized, double-blind, placebo controlled trial.
This will be an 8 week, multicenter, randomized, double blind, placebo controlled trial. The
 screening visit will be divided into two parts, a "pre-screen" in-clinic rapid lipid test
 (Cholestech) followed by a full screening blood draw to be sent to the central reference
 laboratory (CRL) for subjects meeting the Cholestech inclusion values for TG and LDL (see
 inclusion criteria below) on the pre-screen test. Subjects who do not meet the pre-screen
 criteria will be discharged from further participation in the study. Subjects must have
 pre-screen lipid values of LDL >/=70 mg/dl and triglyceride (TG) >/=180 and </=499. Subjects
 who meet these Cholestech criteria will have blood drawn for central reference laboratory
 (CRL) screening testing. For randomization, 80% of the subjects must have TG>/=200 mg/dl to
 proceed to the next screening step while up to 20% will be allowed to proceed to the next
 screening step with TG=150-199 mg/dl as long as the LDL is>/=70 mg/dl. Subjects who meet the
 CRL pre-screen lipid inclusion criteria will return 2-14 days later for the remainder of the
 full screening procedures. Subjects who meet all screening criteria will be randomized at
 this visit. Thus, the prescreening and screening-1 visits will occur at the same time and the
 screening 2 visit will also be the baseline visit. BMI will be calculated but is not a
 criterion for participation.

 Subjects who meet all inclusion and exclusion requirements at the screening 2/baseline visit
 will be randomized to receive one of the two (2) study products. Randomization will proceed
 in groups of 5 with 4 subjects having TG between 200-499 mg/dl before randomizing a subject
 with TG between 150-199 mg/dl. Subjects will return for evaluation 4 and 8 weeks after the
 baseline visit at which times adverse events (AEs) will be recorded, blood lipid studies will
 be done and subjects will complete a VAS for product tolerability. Laboratory studies will be
 drawn after subjects have been sitting for at least 5 minutes.
Inclusion Criteria:

 1. Either gender, in general good health, between 25-85 years old

 2. Serum TG 150-495 mg/dl at screening

 3. Serum LDL >/= 70 mg/dl at screening

 4. Not using any other product including drugs, medical foods, neutraceuticals or dietary
 supplements for control of serum lipids

 5. Consistent dietary habits

 6. Women of child bearing potential must use an accepted method of birth control

 7. Able to read and understand study documents including the Subject Informed Consent
 Document (Spanish language translation available, if needed)

 Exclusion Criteria:

 1. serum TG <150 or >495 mg/dl at screening visit

 2. serum LDL<50 mg/dl at screening visit

 3. use of any other serum lipid modifying agent (see section 6.0) within 4 weeks of
 screening visit

 4. history of any intestinal disease that might interfere with absorption

 5. history of pancreatitis, inflammatory colitis or prior cholecystectomy

 6. any active malignancy or history of malignancy, except basal cell carcinoma or
 cervical carcinoma in situ curatively treated, within 3 years of the screening visit

 7. screening AST, ALT, alkaline phosphatase, bilirubin >1.3 times the upper limit of
 normal for the reference laboratory

 8. serum creatinine >2.0

 9. uncontrolled diabetes mellitus (glycosylated Hgb >9)

 10. diabetes mellitus not on stable therapy for at least 2 months

 11. uncontrolled hypertension (DBP >100, SPB >160)

 12. unstable angina, congestive heart failure or other uncontrolled cardiac disease

 13. pregnant or lactating women

 14. known history of allergies to O-3 fatty acids, carotenoids, vitamin E or fish products

 15. history of substance abuse or any psychiatric condition that may impair the subject's
 ability to comply with the study requirements.

 16. Regular consumption of more than one (1) unit of alcohol daily. For the purposes of
 this study a unit of alcohol consists of 12 oz. of beer, 6 oz. of wine or 2 oz of hard
 spirits.

 17. any medical condition that, in the opinion of the investigator, might put the subject
 at undue risk or might interfere with the subject's ability to participate in the
 study

 18. participation in another clinical trial within 30 days or 6 half lives of the study
 agent, whichever is longer, of the screening visit